Generic versions of Teva's multi-billion-dollar per year multiple sclerosis drug Copaxone (glatiramer) have arrived, but a closer look at which competitor might win the coveted 180-day exclusivity ...

Teva Pharmaceuticals Industries Ltd. dodged some claims and will continue to litigate others in multidistrict litigation brought by drug wholesalers and retailers, as well as a suit brought by a rival ...

Teva Pharmaceutical must face a lawsuit claiming it used unlawful methods to block generic competition for its multiple ...

Viatris likely just lost one of its top product debuts for 2024, thanks to an FDA rejection of its partner Mapi Pharma’s application for a new version of Teva’s multiple sclerosis (MS) drug Copaxone.

Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...

Sanofi shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key goal and U.S. regulators signaling a decision on ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

The FDA on Tuesday approved Novartis’ generic version of Teva Pharmaceutical’s best-selling multiple sclerosis drug, Copaxone, reports Reuters. Here are three things to know. 1. Glatopa, manufactured ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...